Oba01 for advanced lung cancer that has progressed
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called Oba01 for people with advanced non-small cell lung cancer (NSCLC) that has gotten worse after other treatments. It targets a protein called DR5 found on cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old
- Have advanced non-small cell lung cancer (NSCLC) that has spread or can't be surgically removed
- Cancer has gotten worse after at least one prior treatment
- Have tumor tissue available for testing (from a past biopsy or new sample)
- Be in generally good health (able to do daily activities with little help)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests LB1410, a new cancer treatment, to see if it is safe and may work for people with advanced cancers. It focuses on specific cancer types and requires certain prior treatments and lab test results.
This trial tests a new treatment for advanced large-cell neuroendocrine cancer of the lung, a rare type of lung cancer. You may qualify if you've had one round of standard chemotherapy and your cancer has not improved with other treatments.
This Phase 1/2 study tests how well and how safely OSE-279 works in people with advanced non-small cell lung cancer (NSCLC) who cannot be cured with surgery or radiation. It also looks at the right dose and how it may help, especially if the tumor has high PD-L1.
This trial tests an experimental drug called OBI-902 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if OBI-902 can help shrink or control the cancer.
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
This study tests whether adding a new drug called BL-B01D1 to osimertinib (a targeted lung cancer medicine) works better than osimertinib alone. You may qualify if you have advanced lung cancer with an EGFR mutation that didn't get worse after chemotherapy and radiation treatment.
Hear when a new Non Small Cell Lung Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.